Skip to main content
. Author manuscript; available in PMC: 2007 Mar 1.
Published in final edited form as: Am J Physiol Heart Circ Physiol. 2005 Sep 23;290(3):H948–H958. doi: 10.1152/ajpheart.00868.2005

Table I.

Negative Inhibitors of B2R Potentiation

[3H]AA release (relative units; basal release = 1) (n = 3)
Treatment BK BK + thrombin
Vehicle 6.8 ± 0.8 11.8 ± 0.7
Tyr kinase inhibitor genistein 100 μM 6.8 ± 0.4 11.6 ± 0.6
PKG inhib. 0.5 μM (RQIKIWFQNRRMKWKKLRKKKKH) 6.7 ± 0.3 11.7 ± 0.5
PKA inhib. 0.5 μM (H-89, dihydrochloride) 8.6 ± 0.4 11.7 ± 0.5
IP3 kinase inhibitor wortmannin 0.5 μM 6.5 ± 0.6 11.3 ± 0.9
Methyl-β-cyclodextrin 5 mM 6.9 ± 0.6 12.0 ± 0.8